Search Results

Press Releases

Medincell’s Partner Teva Provided Treatment Insights into Switching to UZEDY® from Perseris®

September 23, 2024

·

2 min read

Press Releases

Medincell’s Partner Teva Unveils New Phase 3 Positive Results for Olanzapine LAI, and Presents Real-World Data on UZEDY® at Psych Congress 20241

November 4, 2024

·

2 min read

Press Releases

Medincell’s Partner Teva Presented New Efficacy, Safety, and Tolerability Data from Pivotal Phase 3 of Olanzapine LAI for Adult Patients Diagnosed with Schizophrenia

September 23, 2024

·

2 min read

Business

Medincell Enters Into Strategic Co-development and Licensing Agreement with AbbVie to Develop Next-generation Long-acting Injectable Therapies

Medincell (Paris:MEDCL) today announced a collaboration with AbbVie to co-develop and commercialize up to six therapeutic products across multiple therapeutic areas and indications.

April 16, 2024

·

3 min read

Drug Development

Teva and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable in Adults with Schizophrenia

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd., and Medincell, announced results from the efficacy portion of the Phase 3 Subcutaneous OLAnzapine extended-Release Injection Study trial evaluating TEV-‘749 in adult patients with schizophrenia compared to placebo.

May 8, 2024

·

12 min read

Drug Development

MedinCell’s partner Teva Announces Recruitment Completion of Phase 3 Clinical Study of mdc-TJK / Olanzapine Long-Acting Injectable (LAI)

Teva Pharmaceutical Industries Ltd. announced the successful completion of the enrollment in the EU and US of the anticipated 640 participants of the ongoing Phase 3 clinical trial of mdc-TJK (TEV-44749) at the J.P. Morgan Healthcare Conference.

January 9, 2024

·

2 min read

Drug Development

MedinCell announces successful completion of patient enrollment in the Phase 3 study of F14 (mdc-CWM), a first-in-class therapy for localized pain relief after Total Knee Replacement

MedinCell today announces that its partner, Arthritis Innovation Corporation (AIC), who conducts and finances all development activities of F14 (MedinCell codename: mdc-CWM), has completed the patient enrollment in the first of two Phase 3 clinical studies of F14 in patients undergoing total knee replacement (TKR).

August 30, 2023

·

2 min read

MedinCell’s Partner Teva Announces Successful Launch of UZEDY™

Richard Francis, President and CEO of Teva, and Eric Hughes, Executive Vice President, Global R&D & Chief Medical Officer, commented the US launch of UZEDY since May 2023 and the olanzapine Long-Acting Injectable.

August 2, 2023

·

3 min read

MedinCell’s Partner Teva Today Announced Refiling for Approval of mdc-IRM and Confirmed Planned Launch in the U.S. in H1 2023

MedinCell’s (Paris:MEDCL) partner, Teva, today announced that it recently completed the re-submission to a New Drug Application to the U.S. FDA for mdc-IRM, a risperidone subcutaneous Long-Acting Injectable (LAI) for the maintenance treatment of schizophrenia using MedinCell’s proprietary technology.

November 3, 2022

·

2 min read

Drug Development

MedinCell: mdc-TJK’s (Teva’s codename: TEV-44749) Phase 1 study pharmacokinetics to be presented for the first time by Teva at SIRS 2023 (May 11-15, 2023, Toronto, Canada)

An original presentation describing pharmacokinetic characteristics of an investigational long-acting subcutaneous formulation of olanzapine (mdc-TJK or TEV-44749) will be communicated by MedinCell’s partner Teva Pharmaceuticals at the 2023 Schizophrenia Investigational Research Society (SIRS) later this month.

May 4, 2023

·

2 min read